Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

Phase 3UnknownNCT04320277

Hospital of Prato200 enrolled

Overview

There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2. The drug was found capable to reduce or interrupt the passage of the virus into target cells, and to inhibit the JAK1- and JAK2-mediated cytokine release. The drug was licensed for the treatment of rheumatoid arthritis at the daily dose of 4 mg/orally, with excellent results in terms of clinical response and a good safety profile. Since baricitinib does not interact with antivirals due to its prevalent renal elimination, it may be used in combination.The evidence on the advantageous action of baricitinib on viral entry and cytokine outbreak constituted the rationale to perform a trial on patients with mild to moderate COVID-19 infection receiving baricitinib combined with antiviral therapy.

Study design. Interventional, open-label, 2-week, prospective trial of a cohort of patients with mild to moderate COVID-19 infection. Objectives. Primary. To assess the efficacy of baricitinib combined with antiviral therapy in patients with COVID-19-related mild and moderate disease in terms of reduction of the percentage of subjects requiring ICU admission. Secondary objectives. To describe the clinical findings in a cohort of symptomatic COVID-19-infected subjects; to investigate the role of CRP, IL-6, and TNFα levels as predictor of progression to ARDS; to assess the type and incidence of adverse events (AEs).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All consecutive patients with mild to moderate COVID-19 infection * Age \>18 years, * Clinical diagnosis of COVID19 infection * Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia. * All patients should be willing and able to provide written informed consent prior to performing study procedures. Exclusion Criteria: * Age less than 18 * History of thrombophlebitis. * Patient with latent tuberculosis infection (Quantiferon test). * Pregnancy and lactation.

Outcomes

Primary Outcomes

The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.

The percentage of ICU admission in patients and controls will be compared for statistical difference

Time frame: 2 weeks

Secondary Outcomes

The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.

CRP values will be evaluated for prediction of disease worsening.